



04-10-06

AF/ ~~AM~~
AR/ ~~AR~~

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/208,629	
	Filing Date	December 8, 1998	
	First Named Inventor	Shaun R. COUGHLIN	
	Art Unit	1646	
	Examiner Name	M. Pak	
Total Number of Pages in This Submission	14	Attorney Docket Number	220002060310

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form + duplicate copy for fee processing – 2 pages	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Form PTO/SB/08a/b + copy – 8 pages
<input checked="" type="checkbox"/> Information Disclosure Statement (Supplemental) – 3 pages	<input type="checkbox"/> CD, Number of CD(s) _____	Sixty two (62) references
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	Return Receipt Postcard
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)	
Signature		
Printed name	Debra J. Glaister	
Date	April 7, 2006	Reg. No. 33,888

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 534437624 US, in an envelope addressed to: MS AF, Commissioner-for-Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 7, 2006

Signature: (Georgina Matos)



PTO/SB/17 (12-04v2)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).		Complete if Known	
FEE TRANSMITTAL For FY 2005		Application Number	09/208,629
		Filing Date	December 8, 1998
		First Named Inventor	Shaun R. COUGHLIN
		Examiner Name	M. Pak
		Art Unit	1646
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Attorney Docket No.	220002060310
TOTAL AMOUNT OF PAYMENT		(\$)	180.00

METHOD OF PAYMENT (check all that apply)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card
<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input type="checkbox"/> Other (please identify): _____	
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: 03-1952
Deposit Account Name: Morrison & Foerster LLP	
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
2. EXCESS CLAIM FEES							
Fee Description						Small Entity Fee (\$)	Fee (\$)
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						200	100
Multiple dependent claims						360	180
Total Claims		Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims		
17		- 20 = 0	x 50	= 0.00	Fee (\$)		Fee Paid (\$)
					360		0.00
Indep. Claims		Extra Claims	Fee (\$)	Fee Paid (\$)			
3		- 5 = 0	x 200	= 0.00			
3. APPLICATION SIZE FEE							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets		Extra Sheets	Number of each additional 50 or fraction thereof		Fee (\$)	Fee Paid (\$)	
		- 100 =	/50		(round up to a whole number) x		
4. OTHER FEE(S)							
Non-English Specification, \$130 fee (no small entity discount)						Fees Paid (\$)	
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement						180.00	

SUBMITTED BY			
Signature		Registration No. (Attorney/Agent)	33,888
Name (Print/Type)	Debra J. Glaister	Telephone	(650) 813-5725
		Date	April 7, 2006

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 534437624 US, in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 7, 2006


Signature:

(Georgina Marks)

Patent

Docket No. 220002060310

Client Reference No. 1997-045-2



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Shaun R. COUGHLIN et al.

Serial No.: 09/208,629

Filing Date: December 8, 1998

For: PROTEASE-ACTIVATED RECEPTOR 3
AND USES THEREOF

Examiner: M. Pak

Group Art Unit: 1646

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Applicants thank supervisory Examiner Brenda Brumback for the courtesy of the phone call of March 29, 2006, indicating that the Office Action mailed November 29, 2005 will be vacated. Since the Office Action mailed November 29, 2005 is to be vacated, this application should not have an "After Final" status. However, to avoid any confusion regarding the mail stop for this communication, Applicants have used the mail stop "AF". Since the Office Action mailed November 29, 2005 is to be vacated, Applicants believe this Supplemental Information Disclosure Statement should be considered as timely filed.

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

04/11/2006 SFELEKE1 00000106 031952 09208629

01 FC:1806 180.00 DA

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.


The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;
or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 220002060310.

Dated: April 7, 2006

Respectfully submitted,

By 
Debra J. Glaister

Registration No.: 33,888
MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-5725



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/208,629
				Filing Date	December 8, 1998
				First Named Inventor	Shaun R. COUGHLIN
				Art Unit	1646
				Examiner Name	M. Pak
Sheet	1	of	4	Attorney Docket Number	220002060310

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-5,011,912	04-30-1991	Hopp et al.	
	2.	US-5,688,768-A	11-18-1997	Coughlin et al.	
	3.	US-5,759,994-A	06-02-1998	Coughlin et al.	
	4.	US-5,798,248-A	08-25-1998	Coughlin et al.	
	5.	US-5,849,507-A	12-15-1998	Coughlin	
	6.	US-5,856,448-A	01-05-1999	Coughlin	
	7.	US-5,892,014-A	04-06-1999	Coughlin et al.	
	8.	US-6,024,936-A	02-15-2000	Coughlin et al.	
	9.	US-6,111,075-A	08-29-2000	Xu et al.	
	10.	US-6,124,101-A	09-26-2000	Coughlin	
	11.	US-6,197,541-B1	03-06-2001	Coughlin	
	12.	US-6,436,400-B1	08-20-2002	Xu et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	13.	WO-96/40040-A2,A3	12-19-1996	Incyte Pharmaceuticals, Inc.		
	14.	WO-98/18456-A1	05-07-1998	The Regents of the University of California		
	15.	WO-98/31810-A2,A3	07-23-1998	Schering Corporation		
	16.	WO-99/43809-A2,A3	09-02-1999	The Regents of the University of California		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	17.	Adams, R.L.P. (1980) <u>Laboratory Techniques in Biochemistry and Molecular Biology</u> . Work, T.S. et al., eds. Elsevier, New York, NY, five pages. (Table of Contents only.)	
	18.	An, S. et al. (1997). "Identification of cDNAs Encoding Two G Protein-Coupled Receptors for Lysosphingolipids," <i>FEBS Lett.</i> 417(3):279-282.	
	19.	Ausubel, F.M. et al. (1989). <u>Current Protocols in Molecular Biology</u> . John Wiley and Sons, New York, NY, seven pages. (Table of Contents only.)	
	20.	Brass, L.F. et al. (June 8, 1997). "Thrombin Receptors on Human Platelets: Initial Localization and Subsequent Redistribution During Platelet Activation," <i>Throm. Haem.</i> , XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy, June 6-12, 1997, page 63 (Abstract No. PS-255).	
	21.	Chen, J. et al. (June 10, 1994). "Thrombin Receptor Activation: Confirmation of the Intramolecular Tethered Liganding Hypothesis and Discovery of an Alternative Intermolecular Liganding Mode," <i>J. Biol. Chem.</i> 269(23):16041-16045.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa- 1058579

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/208,629
				Filing Date	December 8, 1998
				First Named Inventor	Shaun R. COUGHLIN
				Art Unit	1646
				Examiner Name	M. Pak
Sheet	2	of	4	Attorney Docket Number	220002060310

22.	Chou, P. Y. et al. (1978). "Empirical Predictions of Protein Conformation," <i>Ann. Rev. Biochem.</i> 47:251-276.
23.	Connolly, T.M. et al. (October 1994). "Species Variability in Platelet and Other Cellular Responsiveness to Thrombin Receptor-Derived Peptides," <i>Thromb. Haemost.</i> 72(4):627-633.
24.	Connolly, A.J. et al. (November 1997). "Mice Lacking the Thrombin Receptor, PAR1, Have Normal Skin Wound Healing," <i>Amer. J. Path.</i> 151(5):1119-1204.
25.	Coughlin, S.R. (July 31, 1997). "Thrombin Signaling in Vivo," <i>FASEB J.</i> 11(9):A1452 (Abstract No. 3483).
26.	Coughlin, S. (October 21, 1997). "How Thrombin Talks to Cells: Molecular Mechanisms and Roles <i>in Vivo</i> ," <i>Circ.</i> 96(8 Suppl.):1-F.
27.	Coughlin, S.R. et al. (October 1994). "Molecular Mechanisms of Thrombin Signaling," <i>Sem. in Hemat.</i> 31(4):270-277.
28.	Coughlin, S.R. et al. (February 1992). "Characterization of a Functional Thrombin Receptor: Issues and Opportunities," <i>J. Clin. Invest.</i> 89(2):351-355.
29.	Fitzpatrick, S.B. et al. (1992). "Use of Peak Flow Monitoring Among Urban Black Children with Asthma," <i>J. Natl. Med. Assoc.</i> 84(6):477-479.
30.	Genbank Accession No. W75830, created on June 20, 1996, located at < http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=1386090&dopt=GenBank >, last visited on April 6, 2006, 2 pages.
31.	Gerszten, R.E. et al. (1993). "All Information Necessary for Thrombin-Receptor Recognition is Contained in the Receptor's Amino Terminal Extension," <i>Circulation</i> 88 (4 Part 2):1-127 (Abstract No. 0671).
32.	Hämmerling, G.J. et al. eds. (1981). <u>Monoclonal Antibodies and T-Cell Hybridomas: Perspectives and Technical Advances</u> . Elsevier, New York, NY, eight pages. (Table of Contents only.)
33.	Hein, L. et al. (1994). "Intracellular Compartmentalization and Trafficking of Thrombin Receptors," <i>Clin. Res.</i> 42(2):331A.
34.	Hein, L. et al. (November 4, 1994). "Intracellular Targeting and Trafficking of Thrombin Receptors: A Novel Mechanism for Resensitization of a G Protein-Coupled Receptor," <i>J. Biol. Chem.</i> 269(44):27719-27726.
35.	Hung, D.T. et al. (1992). "Thrombin-Induced Events in Non-Platelet Cells are Mediated by the Unique Proteolytic Mechanism Established for the Cloned Platelet Thrombin Receptor," <i>J. Cell. Biol.</i> 116(3):827-832.
36.	Hung, D.T. et al. (April 1992). "Cloned Platelet Thrombin Receptor is Necessary for Thrombin-Induced Platelet Activation," <i>J. Clin. Invest.</i> 89(4):1350-1353.
37.	Hung, D.T. et al. (February 1992). "'Mirror Image' Antagonists of Thrombin-Induced Platelet Activation Based on Thrombin Receptor Structure," <i>J. Clin. Invest.</i> 89(2):444-450.
38.	Hung, D.T. et al. (October 15, 1992). "The Cloned Platelet Thrombin Receptor Couples to at Least Two Distinct Effectors to Stimulate Phosphoinositide Hydrolysis and Inhibit Adenylyl Cyclase," <i>J. Biol. Chem.</i> 267(29):20831-20834.
39.	Hurt, C.M. et al. (November 1995). "Constitutive Internalization and Recycling of Thrombin Receptors Allows Receptor Resensitization," <i>Mol. Biol. Cell</i> , The American Society for Cell Biology Thirty-fifth Annual Meeting, December 9-13, 1995, Washington, D.C. 6(Suppl.):285A (Abstract No. 1660).
40.	International Search Report mailed on February 23, 1998 for PCT Application No. PCT/US97/19732 filed on October 29, 1997, four pages.
41.	International Search Report mailed on August 30, 1999 for PCT Application No. PCT/US99/02983 filed on February 11, 1999, three pages.
42.	Ishihara, H. et al. (June 1, 1998). "Antibodies to Protease-Activated Receptor 3 Inhibit Activation of Mouse Platelets by Thrombin," <i>Blood</i> 91(11):4152-4257.
43.	Ishii, K. et al. (January 14, 1994). "Inhibition of Thrombin Receptor Signaling by a G-protein Coupled Receptor Kinase," <i>J. Biol. Chem.</i> 269(2):1125-1130.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/208,629
				Filing Date	December 8, 1998
				First Named Inventor	Shaun R. COUGHLIN
				Art Unit	1646
				Examiner Name	M. Pak
Sheet	3	of	4	Attorney Docket Number	220002060310

44.	Kahn, M. et al. (May 1996). "Conserved Structure and Adjacent Location of the Thrombin Receptor and Protease-Activated Receptor 2 Genes Define a Protease-Activated Receptor Gene Cluster," <i>Mol. Med.</i> 2(3):349-357.
45.	Kahn, M.L. et al. (1997). "Analysis of the Protease-Activated Receptor (PAR) Genomic Locus Reveals the Presence of the Gene Encoding PAR3, a Second Thrombin Receptor and Provides a Means of Investigating the Evolution and Regulation of the Two Known Thrombin Receptors," <i>Circ.</i> 96(8 Suppl.):I-42 (Abstract No. 222).
46.	Kahn, M.L. et al. (June 11, 1997). "Identification of a Novel Human Thrombin Receptor, Protease-Activated Receptor 3 (PAR3)," <i>Thromb. Haem.</i> , pp. 603-604 (Abstract No. OC-2460).
47.	Kahn, M.L. et al. (March 1999). "Protease-Activated Receptors 1 and 4 Mediate Activation of Human Platelets by Thrombin," <i>J. Clin. Invest.</i> 103(6):879-887.
48.	Köhler, G. et al. (August 7, 1975). "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> 256(5517):495-497.
49.	Köhler, G. et al. (April 1976). "Fusion Between Immunoglobulin-Secreting and Nonsecreting Myeloma Cell Lines," <i>Eur. J. Immunol.</i> 6:292-295.
50.	Köhler, G. et al. (July 1976). "Derivation of Specific Antibody-Producing Tissue Culture and Tumor Lines by Cell Fusion," <i>Eur. J. Immunol.</i> 6:511-519.
51.	Kong, W. et al. (April 1996). "Proteinase-Activated Receptor 2 (PAR-2) Regulates Prostaglandin Secretion and CCK Release from Intestinal Epithelial Cells," <i>Gastroenterology</i> 110(4 Suppl):A1089.
52.	Kypson, A.P. et al. (1996). "Global Overexpression of β -Adrenergic Receptors in the Transplanted Rat Heart via Adenoviral-Mediated Gene Transfer," <i>Surgical Forum</i> 47:282-284.
53.	Lerner, D.J. et al. (June 14, 1996). "Agonist Recognition by Proteinase-Activated Receptor 2 and Thrombin Receptor: Importance of Extracellular Loop Interactions for Receptor Function," <i>J. Biol. Chem.</i> 271(24):13943-13947.
54.	McNamara, C.A. et al. (February 1993). "Human Thrombin Receptor Activating Peptide-Induced Proliferation of Cultured Vascular Smooth Muscle Cells is Species Specific," <i>J. Amer. Coll. of Card.</i> 21(2 Suppl. A): 211A (Abstract No. 900-49).
55.	Molino, M. et al. (February 28, 1997). "Thrombin Receptors on Human Platelets: Initial Localization and Subsequent Redistribution During Platelet Activation," <i>J. Biol. Chem.</i> 272(9):6011-6017.
56.	Molino, M. et al. (April 25, 1997). "Endothelial Cell Thrombin Receptors and PAR-2: Two Protease-Activated Receptors Located in a Single Cellular Environment," <i>J. Biol. Chem.</i> 272(17):11133-11141.
57.	Nakanishi-Matsui, M. et al. (April 6, 2000). "PAR3 is a Cofactor for PAR4 Activation by Thrombin," <i>Nature</i> 404:609-613.
58.	Oppermann, M. et al. (July 1996). "Monoclonal Antibodies Reveal Receptor Specificity Among G-Protein-Coupled Receptor Kinases," <i>PNAS</i> 93:7649-7654.
59.	Pouwels, P.H. et al. (1988). <i>Cloning Vectors: A Laboratory Manual</i> . John Wiley and Sons, New York, NY, seven pages. (Table of Contents Only.)
60.	Probst, W.C. et al. (1992). "Sequence Alignment of the G-Protein Coupled Receptor Superfamily," <i>DNA Cell Biol.</i> 11(1):1-20.
61.	Rasmussen, U.B. et al. (August 1991). "cDNA Cloning and Expression of a Hamster α -Thrombin Receptor Coupled to CA^{2+} Mobilization," <i>FEBS Lett.</i> 288(1,2):123-128.
62.	Rydel, T.J. et al. (September 2, 1994). "Crystallographic Structure of Human γ -Thrombin," <i>J. Biol. Chem.</i> 269(35):22000-22006.
63.	Sambrano, G.R. et al. (July 16, 1999). "The Carboxyl Tail of Protease-Activated Receptor-1 is Required for Chemotaxis: Correlation of Signal Termination and Directional Migration," <i>J. Biol. Chem.</i> 274(29):20178-20184.
64.	Sambrook, J. et al. (1989). <i>Molecular Cloning: A Laboratory Manual</i> . Cold Spring Harbor Laboratory Press, New York, NY, 29 pages. (Table of Contents Only.)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa- 1058579

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/208,629
				Filing Date	December 8, 1998
				First Named Inventor	Shaun R. COUGHLIN
				Art Unit	1646
				Examiner Name	M. Pak
Sheet	4	of	4	Attorney Docket Number	220002060310

65.	Shapiro, M.J. et al. (December 20, 1996). "Role of the Thrombin Receptor's Cytoplasmic Tail in Intracellular Trafficking: Distinct Determinants for Agonist-Triggered Versus Tonic Internalization and Intracellular Localization," <i>J. Biol. Chem.</i> 271(51):32874-32880.	
66.	Shapiro, M.J. et al. (December 1996). "The Role of the Cytoplasmic Tail of the Thrombin Receptor in Internalization," <i>Mol. Bio. Cell</i> , Annual Meeting of the 6th International Congress on Cell Biology and the 36th American Society for Cell Biology, December 7-11, 1996, San Francisco, CA Suppl. 7:428a (Abstract No. 2489).	
67.	Skryzpczak-Jankun, E et al. (1991). "Structure of the Hirugen and Hirulog 1 Complexes of α -Thrombin," <i>J. Mol. Biol.</i> 221:1379-1393.	
68.	Stewart, J.M. et al. (1984). <u>Solid Phase Peptide Synthesis</u> . 2nd Edition, Pierce Chemical Company, Rockford, IL, six pages. (Table of Contents only.)	
69.	Trejo, J. et al. (August 30, 1996). "The Cloned Thrombin Receptor is Necessary and Sufficient for Activation of Mitogen-Activated Protein Kinase and Mitogenesis in Mouse Lung Fibroblasts: Loss of Responses in Fibroblasts from Receptor Knockout Mice," <i>J. Biol. Chem.</i> 271(35):21536-21541.	
70.	U.S. Patent Application No. 08/481,896 filed on June 7, 1995 for Coughlin, 81 pages.	
71.	U.S. Patent Application No. 09/392,941 filed on September 9, 1999 for Coughlin, 72 pages.	
72.	Verrall, S. et al. (March 14, 1997). "The Thrombin Receptor Second Cytoplasmic Loop Confers Coupling to G _q -like G Proteins in Chimeric Receptors: Additional Evidence for a Common Transmembrane Signaling and G Protein Coupling Mechanism in G Protein-Coupled Receptors," <i>J. Biol. Chem.</i> 272(11):6898-6902.	
73.	Williams, J.A. et al. (July 1988). "Expression of Receptors for Cholecystokinin and Other Ca ²⁺ -Mobilizing Hormones in <i>Xenopus</i> oocytes," <i>Proc. Natl. Acad. Sci. USA.</i> 85:4939-4943.	
74.	Xu, W. F. et al. (June 1998). "Cloning and Characterization of Human Protease-activated Receptor 4," <i>Proc. Natl. Acad. Sci. USA.</i> 95:6642-6646.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa-1058579